What is the role of vemurafenib in the treatment of hairy cell leukemia (HCL)?

Updated: Sep 16, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

Vemurafnib is a BRAF kinase inhibitor that is approved for use in other diseases that harbor a BRAF V600 mutation. In a multicenter study in Italy and the United States, treatment with vemurafenib (at a dose of 960 mg twice daily) proved effective in patients with relapsed or refractory disease after treatment with a purine analogue. Vemurafenib was given for a median of 16 weeks in the Italian arm and 18 weeks in the US arm. The overall response rates were 96% (25 of 26 patients) after a median of 8 weeks in the Italian cohort and 100% (24 of 24) after a median of 12 weeks in the US cohort. The rates of complete response were 35% (9 of 26 patients) and 42% (10 of 24) in Italy and the US, respectively. [37]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!